Christopher Lieu, MD

Christopher Lieu, MD, is the Co-Director of Gastrointestinal Medical Oncology at the University of Colorado Medicine.

Articles by Christopher Lieu, MD

Christopher Lieu, MDColorectal Cancer | September 11, 2024
Dr. Lieu breaks down his top uses of AI in GI oncology today, as well as their projected applicability in the near future.
View More
Nataliya Uboha, MD, PhDColorectal Cancer | May 1, 2024
Drs. Nataliya Uboha and Christopher Lieu highlight a recent analysis of the KRYSTAL-1 trial for metastatic colorectal cancer.
Christopher Lieu, MDColorectal Cancer | March 19, 2024
Dr. Christopher Lieu gives an overview of the BESPOKE trial and the GALAXY arm of CIRCULATE-Japan, as well as NETTER-2.
Christopher Lieu, MDASCO GI 2024 | January 25, 2024
Dr. Lieu discusses the CIRCULATE-NORTH AMERICA trial on ctDNA status as a biomarker for risk stratification in colon cancer.
Christopher Lieu, MDASCO GI 2024 | January 23, 2024
Dr. Christopher Lieu gives an overview of some of the top presentations and data to look out for at ASCO GI 2024.
Namrata Vijayvergia, MDUnresectable HCC | January 23, 2024
Drs. Vijayvergia and Lieu conclude with considerations for managing IO-related toxicities in patients with metastatic HCC.
Namrata Vijayvergia, MDUnresectable HCC | January 23, 2024
Drs. Vijayvergia and Lieu continue their discussion with attention to biomarkers of response for immunotherapy in mHCC.
Namrata Vijayvergia, MDUnresectable HCC | January 23, 2024
Drs. Vijayvergia and Lieu detail the considerations for administering immunotherapy to their patients with metastatic HCC.
Christopher Lieu, MDUnresectable HCC | January 23, 2024
Drs. Lieu and Lindquist provide an overview of the patient selection criteria for TACE and TARE in unresectable HCC.
Christopher Lieu, MDUnresectable HCC | January 23, 2024
Drs. Lieu and Lindquist detail the histories of TACE and TARE and why TARE may be more effective in treating uHCC.
Christopher Lieu, MDUnresectable HCC | January 23, 2024
Dr. Christopher Lieu talks about the upcoming liver cancer trials he has his eye on.
Christopher Lieu, MDUnresectable HCC | January 23, 2024
Dr. Christopher Lieu talks about the importance of liver cancer screening and educating patients about their risk factors.